Cyclacel Pharmaceuticals Files Q1 2025 10-Q
Ticker: BGMSP · Form: 10-Q · Filed: May 14, 2025 · CIK: 1130166
Sentiment: neutral
Topics: 10-Q, quarterly-report, pharmaceuticals
Related Tickers: CYCC
TL;DR
Cyclacel Pharma filed its Q1 2025 10-Q. All systems go.
AI Summary
Cyclacel Pharmaceuticals, Inc. filed its quarterly report for the period ending March 31, 2025. The company, formerly known as Xcyte Therapies Inc., is incorporated in Delaware and operates in the pharmaceutical preparations sector. Its principal executive offices are located in Berkeley Heights, New Jersey.
Why It Matters
This filing provides investors with an update on Cyclacel Pharmaceuticals' financial performance and operational status for the first quarter of 2025.
Risk Assessment
Risk Level: low — This is a routine quarterly filing providing standard financial and operational information.
Key Players & Entities
- Cyclacel Pharmaceuticals, Inc. (company) — Filer of the 10-Q
- XCYTE THERAPIES INC (company) — Former name of Cyclacel Pharmaceuticals, Inc.
- 20250331 (date) — End of the reporting period
- 20250514 (date) — Filing date
- 0001130166 (company) — Central Index Key for Cyclacel Pharmaceuticals, Inc.
FAQ
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20250331, indicating the filing covers the first quarter of 2025.
When was this 10-Q filed with the SEC?
The filing date is 20250514.
What was Cyclacel Pharmaceuticals, Inc. formerly known as?
The company was formerly known as XCYTE THERAPIES INC.
In which state is Cyclacel Pharmaceuticals, Inc. incorporated?
The company is incorporated in Delaware (DE).
What is the business address of Cyclacel Pharmaceuticals, Inc.?
The business address is 200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding Cyclacel Pharmaceuticals, Inc. (BGMSP).